Search Result

Results for "

lysophosphatidic acid (LPA) receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Biochemical Assay Reagents (2) Cyclophilin (1) Drug Isomer (1) Endogenous Metabolite (1) LPL Receptor (21) MDM-2/p53 (1) PPAR (1) Reactive Oxygen Species (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (3) Endocrinology (2) Infection (2) Inflammation/Immunology (6) Metabolic Disease (3) Neurological Disease (7)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Amino acid Transporter Amino Acid Derivatives Amino Acid Decarboxylase Hydroxycarboxylic Acid Receptor (HCAR) Free Fatty Acid Receptor Fatty Acid Synthase (FASN) Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18076

LPA1 receptor antagonist 1	LPL Receptor	Infection Inflammation/Immunology
LPA1 receptor antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 *(LPA1)* antagonist with an IC₅₀ of 25 nM.

HY-137862

1-Oleoyl lysophosphatidic acid 1 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate; 1-Oleoyl-LPA	LPL Receptor	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) is an abundant lysophosphatidic acid (LPA) species with high biological activity due to its strong affinity for the **LPA receptors*. 1-Oleoyl lysophosphatidic* acid is commonly used in most laboratories as a reagent for LPA receptor activation . 1-Oleoyl lysophosphatidic acid increases SRE-driven β-galactosidase activity .

HY-15706

H2L 5765834	LPL Receptor	Cardiovascular Disease
H2L 5765834 is an antagonist of **lysophosphatidic acid receptors LPA₁, LPA₃, and LPA₅, with IC₅₀**s of 94, 752, and 463 nM respectively .

HY-120478

ASP6432	LPL Receptor	Infection
ASP6432 is a potent and selective type 1 lysophosphatidic acid receptor (LPA1) antagonist with IC₅₀s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively .

HY-114380

Radioprotectin-1	LPL Receptor	Others
Radioprotectin-1 is a potent and specific nonlipid agonist of **lysophosphatidic acid receptor 2 (LPA₂), with an EC₅₀** value of 25 nM for murine LPA₂ subtype .

HY-100882

ONO-7300243	LPL Receptor	Cardiovascular Disease
ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC₅₀ of 0.16 μM.

HY-160173

LPA receptor antagonist-1	LPL Receptor	Others
LPA receptor antagonist-1 (example 52) is an antagonist of lysophosphatidic acid (LPA) receptor. LPA receptor antagonist-1 can be used for kinds of studies .

HY-128127

NAEPA	LPL Receptor	Others
NAEPA, a phosphate-mimetic derivative, is a lysophosphatidic acid (LPA) receptor agonist .

HY-137862A

(Rac)-1-Oleoyl lysophosphatidic acid (Rac)-1-Oleoyl-sn-glycero-3-phosphate; (Rac)-1-Oleoyl-LPA	LPL Receptor Drug Isomer	Neurological Disease
(Rac)-1-Oleoyl lysophosphatidic acid is an isomer of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid that can activate the *LPA* receptors .

HY-160616

LPA5 antagonist 3	LPL Receptor	Cardiovascular Disease Neurological Disease
LPA5 antagonist 3 (Example 74) is a lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC₅₀ of 170 nM. LPA5 antagonist 3 can be used for the research of pain disorders and atherosclerosis .

HY-151392

LPA5 antagonist 2	LPL Receptor	Neurological Disease Inflammation/Immunology
LPA5 antagonist 2 (compound 65) is a high aqueous solubility *LPA5* (lysophosphatidic acid receptor 5) antagonist. LPA5 antagonist 2 significantly attenuates nociceptive hypersensitivity and it can be used for the research of inflammatory and neuropathic pains .

HY-W127502

1-Hexadecylglycero-3-phosphate 1-Hex-GPA	Biochemical Assay Reagents	Others
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

HY-114379

AS2717638 1 Publications Verification	LPL Receptor	Neurological Disease Inflammation/Immunology
AS2717638 is a highly selective, brain-penetrant and orally active **lysophosphatidic acid receptor 5 (LPA5) antagonist with an IC₅₀** value of 38 nM. AS2717638 is highly selective and shows no significant antagonistic activity against other LPA receptors (LPA1, LPA2, and LPA3). AS2717638 can be used in the research of pain and neuroinflammation-related diseases .

HY-W923661

1-Octadecyl lysophosphatidic acid PA(O-18:0/0:0); 1-Oleyl LPA; 1-Octadecyl LPA	LPL Receptor	Others
1-Octadecyl lysophosphatidic acid (compound 10) is a GPR92 receptor (LPA5) activator with potential flavoring effects .

HY-117444

ONO-9780307	LPL Receptor	Cancer
ONO-9780307 is a specific synthetic *LPA1* (lysophosphatidic acid receptor 1) antagonist with an IC₅₀ value of 2.7 nM .

HY-150204

ONO-0740556	LPL Receptor	Inflammation/Immunology
ONO-0740556 is a potent Gi-coupled human lysophosphatidic acid receptor 1 (LPA1) agonist with an EC₅₀ value of 0.26 nM .

HY-139853

BMS-986278 1 Publications Verification	LPL Receptor	Others
BMS-986278 is a potent and orally active **lysophosphatidic acid receptor 1 (LPA1) antagonist, with K_b*s of 6.9 nM and 4.0 nM for human and mouse LPA*1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases .

HY-160003

PPARγ agonist 9	PPAR	Metabolic Disease
PPARγ agonist 9 is an agonist of PPARγ. PPARγ agonist 9 is the analogue of lysophosphatidic acid with an EC₅₀ more than 10 μM for LPA₃ receptor .

HY-107614

1-Oleoyl lysophosphatidic acid sodium 1 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) sodium, a potent bioactive phospholipid, is a **LPA receptor** activator. 1-Oleoyl lysophosphatidic acid sodium can promote mitosis by inducing DNA synthesis. 1-Oleoyl lysophosphatidic acid sodium is also involved in normal and pathological emotional responses, including anxiety and depression .

HY-151391

LPA5 antagonist 1	Biochemical Assay Reagents	Neurological Disease
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high brain permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157693

C18:1 Cyclic LPA	Endogenous Metabolite	Cancer
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

HY-117779

DBIBB 1 Publications Verification	Apoptosis	Endocrinology
DBIBB is a specific nonlipid agonist of the type 2 G protein coupled receptor for lysophosphatidic acid (LPA2). DBIBB mitigates the gastrointestinal radiation syndrome, increases intestinal crypt survival and enterocyte proliferation, and reduces apoptosis. DBIBB represents a agent candidate capable of mitigating acute radiation syndrome caused by high-dose γ-radiation to the hematopoietic and gastrointestinal system .

HY-115450

ONO-0300302	LPL Receptor	Endocrinology Cancer
ONO-0300302 is an orally active and potent *LPA1* (lysophosphatidic acid receptor 1) antagonist, with an IC₅₀ of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with K_d of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .

HY-100619A

BMS-986020 sodium Maximum Cited Publications 8 Publications Verification AM152 sodium	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-100619

BMS-986020 Maximum Cited Publications 8 Publications Verification AM152	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) is a high-affinity and selective **lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 inhibits bile acid and phospholipid transporters with IC₅₀**s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-124072

HL001	Cyclophilin LPL Receptor MDM-2/p53 Apoptosis Reactive Oxygen Species	Cancer
HL001 is an orally active small molecule inhibitor of Cyclophilin A (CypA) and a receptor antagonist of Lysophosphatidic acid 1 (LPA1). HL001 induces cell cycle arrest and apoptosis of tumor cells by p53. HL001 stabilizes p53 by down-regulating G3BP1, inducing reactive oxygen species and DNA damage. HL001 disrupts the interaction between MDM2 and p53-72R in a CypA dependent manner. HL001 has antitumor activity. HL001 can also be used to study pulmonary fibrosis .

Cat. No.	Product Name	Type

HY-W127502

1-Hexadecylglycero-3-phosphate 1-Hex-GPA	Cell Assay Reagents
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83630

	EDG2 Antibody (YA3375) lysophosphatidic acid receptor 1; LPA receptor 1; LPA-1; lysophosphatidic acid receptor Edg-2; LPAR1; EDG2; LPA1	WB, IHC-P, IP	Human
	EDG2 Antibody (YA3375) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3375), targeting EDG2, with a predicted molecular weight of 41 kDa (observed band size: 41 kDa). EDG2 Antibody (YA3375) can be used for WB, IHC-P, IP experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-151391

LPA5 antagonist 1		Alkynes
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high brain permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-157693

C18:1 Cyclic LPA		Phospholipids
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: